Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 14/20 | 0.42 |
| ▸ | CDK9 | P50750 | 14/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | BCR | P11274 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991916 | 0.84 | JAK2 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2988024 | 0.84 | CCNT1 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2988163 | 0.83 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2985432 | 0.83 | CYP19A1 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2988143 | 0.81 | ABL1 (0.44) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL17022950 | 0.80 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2996697 | 0.78 | ALDH1A1 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL8514812 | 0.77 | CCNT1 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2985977 | 0.77 | CCNT1 (0.51) | CYP1A2CYP2D6CYP2C19CLK4USP2 | |
| SCHEMBL8514815 | 0.76 | CYP1A2 (0.65) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | claimed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | claimed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | claimed |
| EP-2137164-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | claimed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | claimed |
| WO-2008129069-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | claimed |
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| EP-2137164-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008129069-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129069-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | CDK5, CDK5R1, CDK1 | CYP1A2 4190/4885CYP3A4 4306/4885CYP2D6 3843/4885 |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | CDK5, CDK5R1, CDK4 | CYP1A2 4545/4885CYP3A4 4048/4885CYP2D6 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.